PMID- 37935702
OWN - NLM
STAT- MEDLINE
DCOM- 20231109
LR  - 20231111
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Nov 6
TI  - Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease 
      using FDA adverse event reporting system.
PG  - 19272
LID - 10.1038/s41598-023-44142-2 [doi]
LID - 19272
AB  - Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson's disease 
      (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors 
      worldwide. Although these drugs inhibit MAO-B, there are pharmacological and 
      chemical differences, such as the inhibitory activity, the non-dopaminergic 
      properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B 
      inhibitors may differ in adverse events (AEs). However, differences in actual 
      practical clinics are not fully investigated. A retrospective study was conducted 
      using FAERS, the largest database of spontaneous adverse events. AE signals for 
      MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected 
      using the reporting odds ratio method and compared. Hypocomplementemia, hepatic 
      cyst, hepatic function abnormal, liver disorder and cholangitis were detected for 
      selegiline as drug-specific signals. The amphetamine effect was not confirmed for 
      any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE 
      signal only for rasagiline. Moreover, the REM sleep behavior disorder was not 
      detected as an AE signal for safinamide, suggesting that non-dopaminergic effects 
      might be beneficial. Considering the differences in AEs for MAO-B inhibitors will 
      assist with the appropriate PD medication.
CI  - (c) 2023. The Author(s).
FAU - Asano, Hiroto
AU  - Asano H
AUID- ORCID: 0000-0002-0973-6773
AD  - Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, 
      Suita, Osaka, 565-0871, Japan.
FAU - Tian, Yu-Shi
AU  - Tian YS
AUID- ORCID: 0000-0002-8988-9453
AD  - Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, 
      Suita, Osaka, 565-0871, Japan. yushi-tian@phs.osaka-u.ac.jp.
FAU - Hatabu, Asuka
AU  - Hatabu A
AUID- ORCID: 0000-0001-9886-1447
AD  - Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, 
      Suita, Osaka, 565-0871, Japan.
FAU - Takagi, Tatsuya
AU  - Takagi T
AUID- ORCID: 0000-0002-0044-0722
AD  - Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, 
      Suita, Osaka, 565-0871, Japan.
FAU - Ueda, Mikiko
AU  - Ueda M
AD  - Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, 
      Suita, Osaka, 565-0871, Japan.
FAU - Ikeda, Kenji
AU  - Ikeda K
AUID- ORCID: 0000-0001-8299-4464
AD  - Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, 
      Suita, Osaka, 565-0871, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231106
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 2K1V7GP655 (Selegiline)
RN  - 003N66TS6T (rasagiline)
RN  - 90ENL74SIG (safinamide)
RN  - EC 1.4.3.4 (Monoamine Oxidase)
RN  - 0 (Dopamine Agents)
RN  - 0 (Amphetamines)
SB  - IM
MH  - Humans
MH  - *Monoamine Oxidase Inhibitors/adverse effects
MH  - *Parkinson Disease/drug therapy
MH  - Selegiline/adverse effects
MH  - Retrospective Studies
MH  - Monoamine Oxidase
MH  - Dopamine Agents/therapeutic use
MH  - Amphetamines
PMC - PMC10630381
COIS- The authors declare no competing interests.
EDAT- 2023/11/08 00:42
MHDA- 2023/11/09 06:42
PMCR- 2023/11/06
CRDT- 2023/11/07 23:22
PHST- 2022/11/02 00:00 [received]
PHST- 2023/10/04 00:00 [accepted]
PHST- 2023/11/09 06:42 [medline]
PHST- 2023/11/08 00:42 [pubmed]
PHST- 2023/11/07 23:22 [entrez]
PHST- 2023/11/06 00:00 [pmc-release]
AID - 10.1038/s41598-023-44142-2 [pii]
AID - 44142 [pii]
AID - 10.1038/s41598-023-44142-2 [doi]
PST - epublish
SO  - Sci Rep. 2023 Nov 6;13(1):19272. doi: 10.1038/s41598-023-44142-2.